Fig. 1

Analysis of NUSAP1 in pan-cancer. a TIMER was used to examine the expression of NUSAP1 in 32 cancers, as seen in a box diagram. Survival analysis in prostate adenocarcinoma (PRAD) (b), renal chromophobe cell carcinoma (KICH) (c), renal papillary cell carcinoma (KIRP) (d), hepatocellular carcinoma (LIHC) (e), lung adenocarcinoma (LUAD) (f), and pan-cancer (g) were shown. The horizontal axis represents the overall survival rate, and the vertical axis represents the month. h TIMER was used to analyze the correlation between the expression level of the NUSAP1 and the infiltration level of six immune cells in LIHC. *p < 0.5, **p < 0.01,  ***p < 0.001